about
Neural correlates of cognitive improvements following cognitive remediation in schizophrenia: a systematic review of randomized trialsCognitive enhancement in schizophrenia: pharmacological and cognitive remediation approachesCurrent approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatmentsCigarette smoking and cognitive function in Chinese male schizophrenia: a case-control studyEffects of the D1 Dopamine Receptor Agonist Dihydrexidine (DAR-0100A) on Working Memory in Schizotypal Personality DisorderSensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers.L-lysine as adjunctive treatment in patients with schizophrenia: a single-blinded, randomized, cross-over pilot study.Aerobic Exercise Improves Cognitive Functioning in People With Schizophrenia: A Systematic Review and Meta-Analysis.Psychometric properties of performance-based measurements of functional capacity: test-retest reliability, practice effects, and potential sensitivity to change.Impaired nerve growth factor homeostasis in patients with bipolar disorder.Cognition, dopamine and bioactive lipids in schizophrenia.Notes from Underground: Are Cognitive-Enhancing Drugs Respecting their Promises?Brain Correlates of Cognitive Remediation in Schizophrenia: Activation Likelihood Analysis Shows Preliminary Evidence of Neural Target EngagementA Multisite, Randomized Controlled Clinical Trial of Computerized Cognitive Remediation Therapy for Schizophrenia.New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal FunctionValidating the measurement of real-world functional outcomes: phase I results of the VALERO studyCognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls.Does antidepressant treatment improve cognition in older people with schizophrenia or schizoaffective disorder and comorbid subsyndromal depression?Current approaches to treatments for schizophrenia spectrum disorders, part II: psychosocial interventions and patient-focused perspectives in psychiatric care.Cognitive function, plasma MnSOD activity, and MnSOD Ala-9Val polymorphism in patients with schizophrenia and normal controls.Cognitive enhancement by drugs in health and diseaseSchizophrenia as a disorder of too little dopamine: implications for symptoms and treatment.The need for experience focused counselling (EFC) with voice hearers in training and practice: a review of the literature.Pharmacological Interventions for the MATRICS Cognitive Domains in Schizophrenia: What's the Evidence?Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.Modeling Deficits From Early Auditory Information Processing to Psychosocial Functioning in Schizophrenia.Evidence for a differential contribution of early perceptual and late cognitive processes during encoding to episodic memory impairment in schizophrenia.Cognitive insight and functional outcome in schizophrenia; a multi-center collaborative study with the specific level of functioning scale-Japanese version.Severity of hypertension predicts the generalized neurocognitive deficit in schizophrenia.Pharmacological Augmentation of Psychosocial and Remediation Training Efforts in Schizophrenia.Sustained NMDA receptor hypofunction induces compromised neural systems integration and schizophrenia-like alterations in functional brain networks.PDE Inhibitors for the Treatment of Schizophrenia.Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia: relationships with clinical phenotypes and cognitive deficits.Grip Strength Is Associated With Cognitive Performance in Schizophrenia and the General Population: A UK Biobank Study of 476559 Participants.Electrophysiological Evidence in Schizophrenia in Relation to Treatment Response.
P2860
Q26753204-2B147F92-5908-46DD-832E-0F9DD3012CABQ26864324-A9A9880E-5CC0-4937-86E5-C2D440A85AACQ27003099-A709ED79-000C-48D1-A901-F01EE901703CQ28730147-55EEBAF5-924F-40BB-8B21-99013BE8BEFDQ29038503-157282E6-9C40-4B04-B79F-89F3C3B1EC89Q30475351-31395766-6807-4DEF-AB4B-02787D4CADAEQ30475497-85FAD2E2-7601-4609-BA27-8F7FAA64425FQ30855177-35226623-D0E7-4893-86D5-6C0AD764FF39Q33846946-931CCEFF-C058-4E9F-A5C9-0C02B5BAC7C1Q34141881-593408D0-6B9F-4493-81FA-6CE1AC8F3531Q34699360-BC1E95ED-B687-4B70-AA46-C6ADEB1A8229Q35157252-EBD2A53A-4513-4841-92DD-8236C0DF0AA4Q36148476-1054519C-3328-479F-91CB-57064DC2403FQ36148500-AF456DBC-AD7F-4654-9C1A-19927EDC0AD6Q36594948-B2BE6CD2-007B-4B33-9D83-D5D38D3C17F6Q36897488-5F853C1A-4386-4145-B2B4-D4A29B9F8190Q36900676-41BA75B9-732E-4930-BEDF-2441C8596AAEQ36983689-811CA7E6-925C-4FB3-8BB7-B1B2F9B6FD7EQ37221010-9CB5D25A-DB3C-4455-91E2-90DF7957591AQ37699340-89684D1E-B28C-42C9-AD7F-75E594079A55Q37819134-8FA0639C-ACBC-4147-9725-E1FF6F01212CQ37862242-954C7E51-8278-4C13-804B-FDA426251C51Q38109947-C2FA455D-A69A-47FF-8693-BC4F9196D323Q38173359-A9AC910A-2BC8-4915-9CA9-530622F01484Q38187948-79A65A47-ABFF-4213-85CF-B7C92A05361FQ39123744-503F82BD-7B55-42F5-A152-D194FE42DF50Q39442631-6653F6E9-9620-4B81-8AC2-3C18BC05DF14Q40109703-9EC42D7F-E6F2-4E5A-9362-0B2C82373EE4Q41657238-728CBBD1-1FB2-44FC-80BB-D006CFA28F8AQ42367850-D1049F82-D284-4B44-A742-A69E18353010Q46477286-AD755AAB-A0F1-4D30-A011-F7F97136747FQ47611419-0EE4EFF5-6E44-43E3-9DA8-4FFD48E7988DQ47891942-35A1B4E4-9162-4C54-9285-8E2ED03114C8Q52569968-F7592A0C-F714-40C0-9D96-78790B51D818Q55312876-3799FC1E-A7BA-40EC-8CD4-5B25C9DCB70E
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacological cognitive enhancement in schizophrenia.
@en
Pharmacological cognitive enhancement in schizophrenia.
@nl
type
label
Pharmacological cognitive enhancement in schizophrenia.
@en
Pharmacological cognitive enhancement in schizophrenia.
@nl
prefLabel
Pharmacological cognitive enhancement in schizophrenia.
@en
Pharmacological cognitive enhancement in schizophrenia.
@nl
P2860
P1476
Pharmacological cognitive enhancement in schizophrenia.
@en
P2093
Philip D Harvey
P2860
P2888
P304
P356
10.1007/S11065-009-9103-4
P577
2009-06-09T00:00:00Z